What's Happening?
As Parkinson's Awareness Month concludes, the focus on advancing research in Parkinson's disease remains critical. With nearly 10 million people affected globally, the disease's impact is significant. Adrian Kells, PhD, senior vice president at AskBio,
emphasizes the need for research that goes beyond symptom management to potentially alter disease progression. Despite challenges in targeting the root cause, advancements in molecular neuroscience, gene delivery, and biomarkers are enabling more targeted investigations. AskBio is actively involved in investigational research, including gene therapy approaches, signaling a shift in understanding and studying Parkinson's disease.
Why It's Important?
The ongoing research in Parkinson's disease is crucial as there is currently no cure or treatment that slows its progression. The unpredictability of symptoms and the need for increased medication over time highlight the necessity for new treatment approaches. Advances in research methodologies offer hope for more effective interventions. The participation of individuals living with Parkinson's in clinical trials is essential for progress, ensuring that new approaches are rigorously evaluated. This research could lead to significant improvements in the quality of life for those affected by Parkinson's, making it a pivotal area of study.
What's Next?
The future of Parkinson's research involves rigorous clinical evaluation of investigational approaches, including gene therapy. Ensuring broad participation in trials is vital to advancing understanding and developing new treatments. The commitment to asking challenging questions and pursuing careful science remains essential. As scientific progress translates into clinical questions, the partnership with the Parkinson's community will be crucial in shaping future care approaches. Continued research and collaboration are necessary to achieve meaningful advancements in Parkinson's treatment.
